All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.
DI-591 is a potent, high-affinity and cell-permeable inhibitor of the DCN1-UBC12 interaction. DI-591 binds to DCN1 and DCN2 with Ki values of 12 nM and 10.4 nM, respectively and has no appreciable binding to DCN3, DCN4, and DCN5 proteins. DI-591 selectively inhibits neddylation of cullin 3 but has no or minimal effect on neddylation of other cullin family members.
| Molecular Weight | 585.8 |
| Formula | C31H47N5O4S |
| CAS Number | 2245887-38-9 |
| Form | Solid |
| Solubility (25°C) | DMSO 12.5 mg/mL (ultrasonic and warming and heat to 60°C) |
| Storage | Powder -20°C |
| Related E1/E2/E3 Enzyme Products |
|---|
| NSC697923
NSC697923 is a cell-permeable and selective inhibitor of the Ub-conjugating enzyme (E2) complex Ubc13-Uev1A. |
| PYR-41
PYR-41 is the first cell-permeable inhibitor of ubiquitin-activating enzyme E1, with no activity at E2. |
| CC0651
CC0651 is an allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme and inhibited the ubiquitination of p27Kip1 with IC50 value of 1.72 μM. |
| Iberdomide
Iberdomide (CC-220) is an orally effective cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC50 for cereblon binding affinity of approximately 150 nM. Iberdomide (CC-220) binds CRBN with higher affinity than lenalidomide and pomalidomide and has enhanced degradation of IKZF1 and IKZF3 with enhanced degradation. |
| Ginkgolic Acid
Ginkgolic Acid is a inhibits SUMOylation by binding E1. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
